CVS Health Corp. and its subsidiaries are facing claims they pocketed over $200 million in overpayments from federal programs after a former compliance director’s False Claims Act (FCA) lawsuit survived a motion to dismiss. The case, filed by whistleblower Michael Gill, will proceed after an Illinois federal judge on Monday allowed significant portions of the suit to continue.

CVS $200M Federal Claims : Allegations of Fraud and Retaliation

Michael Gill, who worked for CVS for decades, filed the lawsuit in 2018, accusing CVS and its subsidiaries of engaging in fraudulent schemes to record millions in overpayments from federal programs as income. Gill also alleged that the company retaliated against him for raising concerns. The whistleblower claimed that CVS used the inflated earnings to pad its adjusted earnings and avoid market consequences.

Court Allows Key Claims to Move Forward

In his ruling, U.S. District Judge Steven C. Seeger found that Gill had sufficiently detailed allegations of overpayments to support FCA claims under federal and Delaware laws. While CVS argued that the overpayments primarily came from commercial payers, Judge Seeger noted the complaint implied government programs were also involved. "‘Primarily’ implies the opposite of ‘entirety,’" Seeger wrote, allowing the claims to proceed.

Gill’s access as a former compliance director also gave him unique insight into the company's practices. His claims against CVS subsidiary Coram, which provides infusion therapy services, were allowed to move forward based on sample contracts Gill provided, even though CVS argued he lacked a “representative example” of fraud.

CVS $200M Federal Claims : Dismissed Claims and Critique of Whistleblower

Despite allowing some claims to proceed, the judge dismissed others, including allegations that CVS improperly accepted drug manufacturer coupons and shipped prescription drugs without proper state licenses. Judge Seeger ruled that the coupons did not constitute illegal kickbacks and found that the shipping issue was already public knowledge, which barred it under the FCA.

Additionally, the court dismissed Gill’s claim under the Illinois Whistleblower Act, criticizing his vague use of passive voice, which failed to identify the specific individuals responsible for his alleged "intolerable work conditions."

Looking Ahead

CVS now faces the continuation of some of the most serious allegations in the case. Gill’s attorney, Daniel R. Hergott, expressed satisfaction with the ruling, stating, "We are eager to move forward and show a jury the evidence supporting these claims."